10-Q · October 31, 2025
Labcorp reported Q3 revenue of $3,563.5 million (up from $3,282.0 million a year ago) with gross profit of $1,025.1 million and operating income of $396.6 million. Diluted EPS was $3.12 versus $2.00 in Q3 2024.…
Earnings analysis · 10-Q
LH earnings analysis
Filed May 4, 2026 · Our reading of the company's report
The latest report
Labcorp Holdings Inc. reported Q1 2026 results with strong revenue growth and a notable EPS beat, demonstrating resilience in its operational performance. Despite increases in some costs, the company maintained its…
Read full summary
Labcorp Holdings Inc. reported Q1 2026 results with strong revenue growth and a notable EPS beat, demonstrating resilience in its operational performance. Despite increases in some costs, the company maintained its margins and significantly improved its cash flow metrics, indicating robust cash generation capabilities.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $4.25
- Segment
- Diagnostic Solutions
- Segment
- BLS
What stood out
-
Strong Revenue Growth
Q1 2026 revenue reached $3.54 billion, up 5.8% from $3.35 billion in Q1 2025.
-
EPS Beat
Diluted EPS for Q1 2026 was $4.25, exceeding the estimate of $4.11.
-
Improved Operating Cash Flow
Net cash provided by operating activities increased to $191.5 million, up from $18.5 million in Q1 2025.
-
Positive Segment Performance
Dx segment revenue rose 5.0% to $2.76 billion, while BLS segment revenue increased 8.2% to $780.6 million.
-
Cost Control Enhancements
Cost of revenues decreased to 71.3% of revenues, improving from 71.7% in the prior year.
-
Increased Cash Reserves
Cash and cash equivalents rose to $981.1 million from $369.4 million in Q1 2025.
What to watch
-
Increased Equity Method Losses
Equity method losses increased to $(5.1) million from $(0.3) million, primarily due to issues related to the SYNLAB investment.
-
Foreign Currency Risks
Foreign currency transaction losses escalated, with net losses of $13.1 million in Q1 2026, indicating exposure to exchange rate fluctuations.
-
Regulatory Changes Impact
Recent changes from the OBBA could affect the revenue and coverage for laboratory tests in future periods.
Management's outlook
Management raised full-year revenue growth guidance to between 5.0% and 6.1%.
Earlier filings 4
10-Q · August 1, 2025
Labcorp reported revenue of $3,527.3M for Q2 (three months ended June 30, 2025), up vs prior quarter and year, with expanding gross and operating margins that drove diluted EPS of $2.84. Operating cash flow for the six…
10-Q · April 29, 2025
Labcorp reported Q1 results with revenue of $3,345.1M, up $168.5M (+5.3%) versus Q1 2024 revenue of $3,176.6M, and gross profit of $948.0M (gross margin ~28.3%). Operating income was $326.0M (operating margin ~9.8%)…
10-Q · October 29, 2024
Labcorp reported Q3 revenues of $3,282.0 million, up $225.2 million versus Q3 2023 ($3,056.8 million), while gross profit rose to $904.4 million but margins compressed and diluted EPS fell to $2.00 from $2.11 a year…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.